Completed PHASE2 INTERVENTIONAL 5-arm NCT00883896

Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY TO SUBJECT WITH RHEUMATOID ARTHRITIS.

Sponsor: Pfizer

Conditions Rheumatoid Arthritis

Interventions ILV-094 Placebo

Updated 9 times since 2017 Last updated: Sep 23, 2022 Started: Jun 18, 2009 Primary completion: Feb 18, 2011 Completion: Feb 18, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Rheumatoid Arthritis and is currently completed. Pfizer leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2022 — Jul 2024 [monthly]

Completed PHASE2
Apr 2022 — Nov 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Antwerp, Belgium , Barranquilla, Colombia , Bogota, Colombia , Brussels, Belgium , Bucaramanga, Colombia , Bucharest, Romania , Budapest, Hungary , Cincinnati, United States , Cluj-Napoca, Romania and 33 more locations